Coronary disease & ACS

Heart Rate and Cardiovascular Outcomes in Post–Myocardial Infarction Patients Treated by β-Blockers: A Secondary Analysis of the ABYSS Trial

CirculationPublished Secondary analysis of the ABYSS randomised trial

Authors' conclusion

In stabilized post-MI patients with preserved ejection fraction, higher HR remains associated with adverse cardiovascular events and mortality in the reperfusion era.

Study context

Population
Stable post-MI patients (LVEF ≥40%) randomised to continue or interrupt β-blockers
Participants
3,698 patients
Comparison
Prerandomization HR tertiles; β-blocker continuation vs interruption
Primary endpoint
Death, MI, stroke or CV rehospitalization
Methodological detailsprespecified
  • Prespecified

Primary result

As reported in the abstract

Primary end point (death, MI, stroke or CV rehospitalization) by baseline HR tertile

Baseline HR not associated with primary end point (T1 <60 bpm vs T2 60 to <68 vs T3 ≥68)

22.4% versus 21.8% versus 21.6%; P=0.867

Secondary outcomes

OutcomeT1T2T3Adjusted HR (95% CI)
Death, MI or strokeT3 vs T15.5%6.4%9.2%1.55 (1.14–2.12)
Death, MI, stroke or HFT3 vs T16.5%7.1%10.4%1.47 (1.11–1.97)

All-cause mortality

  • Death, myocardial infarction (MI) or stroke: across tertiles P<0.001
  • Death, MI, stroke or HF: across tertiles P=0.007
  • All-cause mortality: P=0.004
  • All-cause mortality: P trend=0.008

On-treatment HR after β-blocker interruption · during follow-up

Dose-dependent HR increase with interruption
≈10-13 bpm

Interruption vs continuation, by HR tertile and LVEF category

Association of interruption with worse outcomes consistent across HR tertiles (no significant interaction) and LVEF categories (40% to 49% and >50%)

Original publication

Heart Rate and Cardiovascular Outcomes in Post–Myocardial Infarction Patients Treated by β-Blockers: A Secondary Analysis of the ABYSS Trial. Circulation. Published 10 June 2026. doi:10.1161/circulationaha.125.078635

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.